# Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers

> **NCT01204112** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Tasocitinib (CP-690,550) plus Rifampin

## Key facts

- **NCT ID:** NCT01204112
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2010-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01204112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01204112, "Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01204112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*